SOURCE: Eisai Inc

August 15, 2005 08:00 ET

Eisai Inc. Announces Appointment of Vice President and General Counsel

TEANECK, NJ -- (MARKET WIRE) -- August 15, 2005 -- Eisai Inc. today announces the immediate appointment of Douglas B. Snyder as Vice President and General Counsel. Mr. Snyder will be responsible for all legal matters of the company.

Mr. Snyder joined Eisai from GlaxoSmithKline (GSK) where he served as vice president and associate general counsel. His responsibilities included legal services for sales and marketing, research and development, manufacturing and other functions as well as management of litigation, contract and regulatory activities.

Prior to GlaxoSmithKline, Mr. Snyder was associate chief counsel at the U.S. Food & Drug Administration (FDA), working with the FDA Commissioner, the Center for Drug Evaluation and Research, and congressional and other government officials on legislative and regulatory issues.

"As a human health care company whose mission is to satisfy unmet medical needs and increase benefits for patients and their families, Mr. Snyder will carry forth Eisai's commitment to compliance with all laws and regulations that govern our business," said Lonnel Coats, President & COO. "Mr. Snyder's extensive and valuable experience will most certainly benefit Eisai and its continued successful operations."

About Eisai Inc.

Eisai Inc. is a US pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products in more than 30 countries. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2 billion in fiscal year 2004 (year ended March 31, 2005).

Eisai Inc. employs approximately 1,200 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. Between 1998 and 2004, Eisai Inc. moved up rapidly in the rankings (based on revenues) of US pharmaceutical companies from No. 44 to No. 19.

Contact Information

  • Contacts:
    Cathy Pollini
    Eisai Inc.

    Anna Blank
    Hill & Knowlton